Press releases & news
2CUREX PUBLISHES INTERIM REPORT FOR THE FOURTH QUARTER AND FULL YEAR OF 2023 AND FINANCIAL AND STRATEGIC OUTLOOK FOR 2024Read more
NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF 2CUREX AB (PUBL)Read more
KALLELSE TILL EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)Read more
2cureX announces changes to the Board of Directors.Read more
Share InformationSee our latest share information
Calendar & upcoming events
2cureX Webcast – Join us at 20:00 CET on October 26 for the latest news from the third quarter of 2023 and a Q&A with the 2cureX Management.Watch webcast
Commentary on Q2 2023 report – Infront Direkt Studios will host an interview with CEO Fernando Andreu regarding the results presented in the Q2 2023 report.Watch webcast
2cureX Webcast – Get the latest news from the second quarter of 2023 and Q&A with the Management of 2cureX.Watch webcast
STAY UPDATED WITH OUR NEWS AND PRESS RELEASES
Get notified by mail when news or press releases are published on our website.
In this latest blog, Fernando Andreu talks about the exciting expansion of the IndiTreat® product family to include a functional drug sensitivity test for pancreatic cancer in the near future.
Subscribe to our newsletter above.More
Information for Oncologists and Pathologists
Know more when it matters most:
With our IndiTreat® tests you can finally obtain personalised information, even on the classic compounds for the main chemotherapy backbone for your stage IV mCRC patients.
Information for Patients
You’ve been diagnosed with colorectal cancer, and it is in stage IV. There are rational treatment choices to be made. Which therapy is more likely to impact the tumor? Ask your doctor about IndiTreat®.More